Asian Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown, С. 101063 - 101063
Опубликована: Апрель 1, 2025
Язык: Английский
Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)
Опубликована: Янв. 28, 2024
The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application personalized antigens, structural optimization mRNA, alternative RNA-based vectors efficient targeted delivery vectors. Clinical trials are currently underway for various that encode tumor-associated antigens (TAAs), tumor-specific (TSAs), or immunomodulators. In this paper, we summarize mRNA emergence expression in vaccines. We begin by reviewing advancement utilization state-of-the-art lipid nanoparticles (LNPs), followed presenting primary classifications clinical applications Collectively, emerging as a central focus immunotherapy, offering potential to address multiple treatment, either standalone therapies combination with current treatments.
Язык: Английский
Процитировано
42
Molecular Cancer, Год журнала: 2024, Номер 23(1)
Опубликована: Июнь 1, 2024
Abstract Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during previous ten years. However, its effectiveness treating solid tumors is still lacking, necessitating exploration alternative immunotherapies that can overcome significant challenges faced by current CAR-T cells. CAR-based immunotherapy against shows promise with emergence macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and ability to modify tumor microenvironment stimulate adaptive responses. This paper presents a thorough examination latest progress CAR-M therapy, covering both basic scientific studies clinical trials. study examines primary obstacles hindering realization complete potential as well strategies be employed these hurdles. With revolutionary technologies like situ genetic modification, synthetic biology techniques, biomaterial-supported gene transfer, provide wider array resources manipulating tumor-associated we suggest combining advanced methods will result creation new era therapy demonstrates improved efficacy, safety, availability. Graphical
Язык: Английский
Процитировано
22
Trends in biotechnology, Год журнала: 2023, Номер 42(2), С. 228 - 240
Опубликована: Сен. 21, 2023
Язык: Английский
Процитировано
24
Biomarker Research, Год журнала: 2024, Номер 12(1)
Опубликована: Авг. 23, 2024
Abstract With the advent of adoptive cellular therapy, chimeric antigen receptor (CAR)-T cell therapy has gained widespread application in cancer treatment and demonstrated significant efficacy against certain hematologic malignancies. However, due to limitations CAR-T treating solid tumors, other immune cells are being modified with CAR address this issue. Macrophages have emerged as a promising option, owing their extensive functions, which include presentation, powerful tumor phagocytosis, particularly active trafficking microenvironment. Leveraging unique advantages, CAR-macrophages (CAR-M) expected enhance effectiveness treatments novel form immunotherapy, potentially overcoming major challenges associated CAR-T/NK therapy. This review outlines primary mechanism underlying CAR-M recent progressions while also discussing further applications.
Язык: Английский
Процитировано
15
Advanced Materials, Год журнала: 2024, Номер 36(15)
Опубликована: Янв. 17, 2024
In the past decade, adoptive cell therapy with chimeric antigen receptor-T (CAR-T) cells has revolutionized cancer treatment. However, complexity and high costs involved in manufacturing current greatly inhibit its widespread availability access. To address this, situ therapy, which directly reprograms immune inside body, recently been developed as a promising alternative. Here, an overview of recent progress development synthetic nanomaterials is provided to deliver plasmid DNA or mRNA for reprogramming T macrophages, focusing especially on CAR therapies. Also, main challenges are discussed some approaches overcome these barriers fulfill clinical applications proposed.
Язык: Английский
Процитировано
10
Journal of Materials Chemistry B, Год журнала: 2024, Номер 12(20), С. 4759 - 4784
Опубликована: Янв. 1, 2024
This paper provides a comprehensive review of the structure, composition, and applications LNPs in treatment hepatic disorders offers insights into prospects challenges future development LNPs.
Язык: Английский
Процитировано
10
Journal of Advanced Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
After significant advancements in tumor treatment, personalized cell therapy based on chimeric antigen receptors (CAR) holds promise for transforming the management of various diseases. CAR-T therapy, first approved CAR product, has demonstrated therapeutic potential treating infectious diseases, autoimmune disorders, and fibrosis. CAR-macrophages (CAR-Ms) are emerging as a promising approach immune particularly solid highlighting feasibility using macrophages to eliminate pathogens abnormal cells.
Язык: Английский
Процитировано
2
Nature Biotechnology, Год журнала: 2025, Номер 43(4), С. 516 - 533
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
2
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2025, Номер 1871(3), С. 167676 - 167676
Опубликована: Янв. 18, 2025
Язык: Английский
Процитировано
1
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Март 6, 2025
Cancer-associated myeloid cells due to their plasticity play dual roles in both promoting and inhibiting tumor progression. Myeloid with immunosuppressive properties a critical role anti-cancer immune regulation. Cells of different origin, such as associated macrophages (TAMs), neutrophils (TANs), derived suppressor (also called MDSCs) eosinophils are often expanded cancer patients significantly influence survival, but also the outcome therapies. For this reason, variety preclinical clinical studies modulate activity these have been conducted, however without successful date. In review, pro-tumor cells, cell-specific therapeutic targets, vivo on cell re-polarization impact immunotherapies/genetic engineering addressed. This paper summarizes ongoing trials concept chimeric antigen receptor macrophage (CAR-M) therapies, suggests future research perspectives, offering new opportunities development novel treatment strategies.
Язык: Английский
Процитировано
1